Browsing: STAT+

A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have compared to a standard treatment, data presented Friday show. While that efficacy doesn’t match the performance of a rival drug from Roche, Novartis’ treatment has a cleaner safety profile that could give it a shot…

Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit and those that do were generated by a small number of drugmakers, mostly based in Asia, according to a new analysis.

Since five members of the American Diabetes Association were ejected from its scientific session in New Orleans on June 5, the professional organization has released two explanations, one apology, one summary of its review of the events, and one notice of further review. Members have protested through petitions and an 1,100-member boycott. The flagship journal…

Bristol Myers Squibb on Friday reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial, adding to safety concerns about a growing field of research.

You’re reading our ESMO in 30 Seconds newsletter. Sign up here to get updates from the major European cancer conference in your inbox.

The combination of an experimental drug from Tango Therapeutics and Revolution Medicines’ Rasonque led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, clinical trial results reported Friday showed

Gilead Sciences agreed to pay $45 million to settle allegations of paying kickbacks that improperly influenced prescriptions paid for by the Texas Medicaid program, the latest pharmaceutical company to reach a deal with the state over marketing practices.

An experimental Huntington’s drug from Alnylam Pharmaceuticals showed promise in a small study, the company said Friday, suggesting it can partially silence the mutant gene that drives the devastating neurological disorder.

Everywhere you look this week, it seems everyone has a hot take on the new Elizabeth Holmes documentary, “You Can See Everything.”We’ve even published a couplehere on this very site. 

Presidential sessions at top cancer meetings typically feature practice-changing clinical trials, detailed in front of thousands of global experts packed into rooms so cavernous they merit their own ZIP codes. But last year, at the most important European oncology conference, one slot was reserved for a presentation of early results from a German biotech’s study…